Overview

• Novo Nordisk has twice lowered its revenue and profit forecasts this year after its new weight-loss drug Cagrisema fell short of expectations.
• Up to 30% of U.S. market volume has shifted to lower-priced generics, spurring lawsuits against 14 manufacturers.
• Competition from Eli Lilly’s Orforglipron and an anticipated oral semaglutide launch next year threatens the company’s U.S. market share.
• Goldman Sachs keeps a buy rating on Novo Nordisk, but other analysts like DZ Bank have adopted more cautious hold stances.
• Investors face a dilemma between betting on a potential recovery and weighing lingering legal, regulatory, and competitive headwinds.